1. Overview of study populations.

	Intervention(s) and comparator(s)	Sample sizea	Screened/eligible [N]	Randomised [N]	Safety [N]	ITT [N]	Finishing study [N]	Randomised finishing study [%]	Follow‐up timeb
Hero 2005	I: letrozole	31 (80% power to detect a difference in PAH between groups of 5 cm and allow for up to a 10% drop‐out rate)	40	16	16	16	16	100	2 years
	C: placebo			15	15	15	14	93
	total:			31	31	31	30	97
Mauras 2008	I: GH plus anastrozole 1 mg	‐	‐	26	26	26	N/A	N/A	12‐36 months
	C: GH plus placebo			26	26	26	N/A	N/A
	total:			52	52	52
Salehpour 2010	I1: letrozole 2.5 mg	15 in each group (90% power, based on the data of Wickman 2001)	91	31	31	31	31	100	2 years
	I2: oxandrolone 2.5 mg			30	30	30	30	100
	C: placebo			30	30	22	22	73
	total:			91	91	83	83	91
Wickman 2001	I: testosterone plus letrozole 2.5 mg	‐	33	11	11	9	9	82	18 months
	C1: testosterone plus placebo			12	12	10	10	83
	C2: untreated (non‐randomised)			10	10	7	7	70
	total:			33	33	26	26	79
Grand total	All interventions			84			Not estimablec
	All comparators			123 (113 randomised)
	All interventions and comparators			207

^aAccording to power calculation in study publication or report.
 ^bDuration of intervention or follow‐up, or both under randomised conditions until end of study.
 ^cNot estimable as allocations of withdrawals and exclusions not provided by Mauras 2008.

C: comparator; GH: growth hormone; I: intervention; ITT: intention‐to‐treat; N: number of participants; N/A: not applicable; PAH: predicted adult height.